Share on LinkedInShare on LinkedIn

ARTICLE · 04 SEPTEMBER 2019

Federal Circuit Finds Method Withholding Treatment Ineligible For Patenting

In its non-precedential decision in INO Therapeutics LLC v. Praxair Distribution Inc., the Federal Circuit agreed with the district court that method of treatment claims reciting "excluding"

United StatesIntellectual Property

In its non-precedential decision in INO Therapeutics LLC v. Praxair Distribution Inc., the Federal Circuit agreed with the district court that method of treatment claims reciting “excluding” specific patients from treatment were ineligible for patenting under 35 USC § 101. Stakeholders in the personalized medicine space likely are hoping that this decision will be cabined to the specific claims at issue, and not herald new scrutiny of more typical personalized medicine claims.

The INOMax® Patents At Issue 

The underlying ANDA litigation involved a number of Orange Book-listed patents for INOMax®, including U.S. Patent No. 8,282,966, U.S. Patent No. 8,293,284, U.S. Patent No. 8,795,741, U.S. Patent No. 8,431,163, and U.S. Patent No. 8,846,112. INOMax® is a nitric oxide delivery system indicated for use to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in neonatal patients with hypoxic respiratory failure associated with clinical or

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from